Expression of ERα and ERβ in lobular carcinoma in situ

Histopathology

Volumn 50, Issue 7, 2007, Pages 875-880

  Middleton, L P ^a   Perkins, G H ^a   Tucker, S L ^a   Sahin, A A ^a   Singletary, S E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Lobular carcinoma in situ; Oestrogen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; UVOMORULIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; BREAST CANCER; CARCINOMA IN SITU; CLINICAL ARTICLE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STROMA CELL; BREAST TUMOR; CELL NUCLEUS; DISEASE FREE SURVIVAL; FEMALE; MAMMOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CELL NUCLEUS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 34249775475     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02689.x     Document Type: Article

References (28)

1. Knight WA, Livingston RB, Gregory BH et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 37 4669 4771.
2. Maas H, Engle B, Trams G. Steroid hormone receptors in human breast cancer and their clinical significance. J. Steroid Biochem. 1975 6 743 749.
3. Wittlift JL. Specific receptors of the steroid hormones in breast cancer. Semin. Oncol. 1974 1 109 118.
4. Rudas M, Neumayer R, Ganant MFX et al. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur. J. Cancer 1997 33 39 44.
5. Giri DD, Dundas SAC, Nottingham JF et al. Oestrogen receptors in benign epithelial lesions and intraductal carcinoma of the breast: an immunohistological study. Histopathology 1989 15 575 584.
6. Bur ME, Zimarowski MJ, Schnitt SJ et al. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992 69 1174 1181.
7. Pallis L, Wilking N, Cedermark B et al. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res. 1992 12 2113 2116.
8. Albonico G, Querzoli P, Ferretti S et al. Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect. Prevent. 1998 22 313 318.
9. Li CO, Anderson BO, Daling JR et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res. Treatment 2002 75 259 268.
10. Fisher B, Constantio JP, Wickerman DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 1998 90 1371 1388.
11. Rosen PP, Kosloff C, Lieberman PH et al. Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am. J. Surg. Pathol. 1978 2 225 251.
12. Page DL, Anderson TJ, Rogers LN. Lobular carcinoma in situ. In Page DL, Anderson TJ eds. Diagnostic histopathology of the breast. New York : Churchill Livingston 1987 174 182.
13. Elston CW, Ellis IO, Goulding H, Pinder SE. Role of pathology in the prognosis of management and breast cancer. In Elston CW, et al. eds. The breast: systemic pathology, 3rd edn, Vol. 13. Edinburgh : Churchill Livingstone 1998 384 433.
14. Umemura S, Itoh J, Itoh H et al. Immunohistochemical evaluation of hormone receptors in breast cancer. Appl. Immunohistochem. Mol. Morphol. 2004 12 8 13.
15. Page DL, Schuyler PA, Dupont WD et al. A typical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003 361 125 129.
16. Page DL, Kidd TE Jr., Dupont WD et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum. Pathol. 1991 22 1232 1239.
17. Lakhani S, Collins N, Sloane J et al. Loss of heterozygosis in lobular carcinoma in situ of the breast. J. Clin. Pathol. Mol. Pathol. 1995 48 M74 M78.
18. Nayar R, Zhuang Z, Merino MJ et al. Loss of heterozygosis on chromosome 11q13 in lobular lesions of the breast using tissue micro dissection and polymerase chain reaction. Hum. Pathol. 1997 28 277 282.
19. Hwang ES, Nyante SJ, Chen YY et al. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 2004 100 2562 2572.
20. du Toit RS, Locker AP, Ellis IO et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur. J. Surg. Oncol. 1991 17 251 257.
21. Frost AR, Terahata S, Yeh I, Siegal RS, Overmoyer B, Silverberg SG. An analysis of prognostic features in infiltrating lobular carcinoma of the breast. Mod. Pathol. 1995 8 830 836.
22. Sneige N, Wang J, Baker BA et al. Clinical, histopathologic, and biologic features of pleomorphic lobular (ducto-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod. Pathol. 2002 10 1044 1050.
23. Leygue E, Watson PH, Murphy LC. Expression of estrogen receptor-beta in human breast tumors. J. Clin. Endocrinol. Metab. 1997 82 2371 2374.
24. Jarvinen TA, Pelto-Huikko M, Holli K et al. Estrogen receptor beta is coexpressed with ER alpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 2000 156 29 35.
25. Mann S, Laucirica R, Carlson N et al. Estrogen receptor beta expression in invasive breast cancer. Hum. Pathol. 2001 32 113 118.
26. Shaaban AM, Jarvis C, Moore F et al. Prognostic significance of estrogen receptor beta in epithelial hyperplasia of usual type with known outcome. Am. J. Surg. Pathol. 2005 29 1598 1599.
27. Liberman L, Sama M, Susnik B et al. Lobular carcinoma in situ percutaneous breast biopsy: surgical biopsy findings. Am. J. Roentgenol. 1999 173 291 299.
28. Middleton LP, Grant S, Stephens T et al. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod. Pathol. 2003 16 120 129.